Novo Nordisk’s triple agonist UBT251 delivered a mean weight loss of 19.7% after 24 weeks in a Phase 2 trial in China, the company announced on Tuesday. UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G) and is being jointly developed with United Biotechnology. The trial was conducted by…
